Tag: Jazz Pharmaceuticals

Pfenex Earned $11m under Development and License Agreement with Jazz Pharma

Pfenex Inc. announced that it has earned an $11 million development milestone under its development and license agreement with Jazz Pharmaceuticals. The milestone is associated with process developmen...

Jazz Pharma Acquired Clinical-Stage Biotech Cavion

Jazz Pharmaceuticals plc announced the acquisition of Cavion, Inc. through a merger with a Jazz subsidiary. Under the terms of the agreement, the former Cavion shareholders receive an upfront payment ...

First Dual-Acting DNRI to Treat Daytime Sleepiness Approved by FDA

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associate...

Jazz Pharmaceuticals and Codiak to R&D Cancer Treatment

Jazz Pharmaceuticals plc and Codiak BioSciences, Inc. announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of e...

Vyxeos obtained marketing authorisation in Europe

drug-development
Jazz Pharmaceuticals announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion.

Jazz Pharmaceuticals and MD Anderson Cancer Center entered into collaboration

cancer-diagnostics
Jazz Pharmaceuticals and The University of Texas MD Anderson Cancer Center announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies.